Who makes ABI-H3733 Solid Oral Dosage Form?

ABI-H3733 Solid Oral Dosage Form is developed by Assembly Biosciences.

What development phase is ABI-H3733 Solid Oral Dosage Form in?

ABI-H3733 Solid Oral Dosage Form is in Phase 1.

Last reviewed 2026-05-15 · How we verify

ABI-H3733 Solid Oral Dosage Form

Assembly Biosciences · Phase 1 active Small molecule Quality 3/100

At a glance

Generic name	ABI-H3733 Solid Oral Dosage Form
Sponsor	Assembly Biosciences
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABI-H3733 Solid Oral Dosage Form CI brief — competitive landscape report
ABI-H3733 Solid Oral Dosage Form updates RSS · CI watch RSS
Assembly Biosciences portfolio CI